KALA BIO — Third Quarter 2026 Earnings Summary

KALA BIO reported a preliminary net loss of approximately $0.8 million for the third quarter of 2026, a significant reduction from the $7.6 million loss in the same period of 2025. For the nine months ended September 30, 2026, the company recorded a net loss of roughly $4.0 million compared to $27.7 million in the prior year. As of September 30, 2026, the company held approximately $7.0 million in cash, cash equivalents, and short-term investments with no outstanding debt. KALA BIO, a clinical-stage biopharmaceutical company, operates a dual strategy combining a biologics pipeline with an on-premises AI infrastructure platform for the biotechnology industry.